Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza
暂无分享,去创建一个
G. Opdenakker | P. Proost | A. Wilmer | E. Wauters | R. E. Marques | D. Schols | G. Hermans | J. Vandooren | J. Wauters | L. Vanderbeke | E. Heylen | M. Metzemaekers | M. Gouwy | B. Malengier-Devlies | P. Meersseman | P. Matthys | A. Carvalho | S. Cambier | Amber Nooyens | Cato Jacobs | Contagious Consortium | Mieke Metzemaekers
[1] R. Zimmer,et al. Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19 , 2021, JCI insight.
[2] A. Ellebedy,et al. Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19 , 2021, The Journal of Immunology.
[3] T. van der Poll,et al. Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients , 2021, Frontiers in Immunology.
[4] A. Gómez-Mejia,et al. Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients , 2021, Cell Reports Medicine.
[5] A. Duhamel,et al. Protease-antiprotease imbalance in patients with severe COVID-19 , 2021, Clinical chemistry and laboratory medicine.
[6] Guangwei Luo,et al. The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression , 2021, The Journal of Immunology.
[7] R. Root-Bernstein. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions , 2021, International journal of molecular sciences.
[8] M. Si-Tahar,et al. Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia , 2021, European Respiratory Journal.
[9] P. Póvoa,et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study , 2021, Intensive Care Medicine.
[10] C. Wouters,et al. Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019 , 2021, Clinical & translational immunology.
[11] D. Wichmann. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.
[12] J. Perfect,et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance , 2020, The Lancet Infectious Diseases.
[13] S. Keshavjee,et al. Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-Inflammation , 2020, Frontiers in Pharmacology.
[14] A. Šedivá,et al. Neutrophils mediate Th17 promotion in COVID-19 patients , 2020, Journal of leukocyte biology.
[15] E. Chan,et al. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19 , 2020, Medical Hypotheses.
[16] G. D'offizi,et al. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome , 2020, Cell Death & Disease.
[17] A. Thierry. Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19 , 2020, Physiological Reviews.
[18] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[19] A. O'donnell,et al. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. , 2020, The New England journal of medicine.
[20] N. Koulouris,et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison , 2020, Nature Immunology.
[21] I. Amit,et al. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing , 2020, medRxiv.
[22] I. Amit,et al. Deciphering the state of immune silence in fatal COVID-19 patients , 2020, Nature Communications.
[23] I. Amit,et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 , 2020, Cell.
[24] E. Arbustini,et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome , 2020, BMC Pulmonary Medicine.
[25] J. Raes,et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity , 2020, Nature Communications.
[26] C. Dooms,et al. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages , 2020, Cell Research.
[27] Konrad U. Förstner,et al. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients , 2020, Genome Medicine.
[28] Roland Eils,et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.
[29] Li Yang,et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage , 2020, Journal of Translational Medicine.
[30] Fang Lin,et al. Clinical and pathological investigation of severe COVID-19 patients. , 2020, JCI insight.
[31] Lin Cheng,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[32] A. Heinz. Elastases and elastokines: elastin degradation and its significance in health and disease , 2020, Critical reviews in biochemistry and molecular biology.
[33] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.
[34] P. Proost,et al. Neutrophil chemoattractant receptors in health and disease: double-edged swords , 2020, Cellular & Molecular Immunology.
[35] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[36] L. Koenderman,et al. The Neutrophil Life Cycle. , 2019, Trends in immunology.
[37] P. Kubes,et al. The Neutrophil's Role During Health and Disease. , 2019, Physiological reviews.
[38] A. Rossi,et al. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential , 2019, The Journal of pathology.
[39] Hans Anton Schlößer,et al. Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.
[40] G. Opdenakker,et al. Neutrophils and Activated Macrophages Control Mucosal Immunity by Proteolytic Cleavage of Antileukoproteinase , 2018, Front. Immunol..
[41] J. Faith,et al. Neutrophil ageing is regulated by the microbiome , 2015, Nature.
[42] A. M. Houghton. Matrix metalloproteinases in destructive lung disease. , 2015, Matrix biology : journal of the International Society for Matrix Biology.
[43] C. Weber,et al. Rhythmic Modulation of the Hematopoietic Niche through Neutrophil Clearance , 2013, Cell.
[44] L. Cosmi,et al. Evidence for a cross-talk between human neutrophils and Th17 cells. , 2010, Blood.
[45] R. Dwek,et al. The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.
[46] J. O'neil,et al. Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. , 1997, Blood.
[47] L. Kjeldsen,et al. Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. , 1995, Journal of immunology.
[48] J. van Beeumen,et al. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity , 1988, The Journal of experimental medicine.
[49] Daishi Tian,et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China , 2020 .
[50] J. Sallenave,et al. SLPI and elafin: one glove, many fingers. , 2006, Clinical science.